Abstracts

1096 – Impact of COVID-19 Healthcare Disruptions on ART Initiation and Viral Suppression: US, 2018-2021

Background Rapidly initiating antiretroviral therapy (ART) and achieving viral suppression (VS) among newly diagnosed people with HIV (PWH) are cornerstones of HIV care. COVID-19 caused far-reaching disruptions in health services, including for HIV treatment and laboratory monitoring. We characterized trends in early ART (eART) and early VS (eVS) among PWH before (2018-2019) vs. during (2020-2021)…

1092 – Mpox Reinfections in California, May 2022 to August 2024

Background At the onset of the 2022 global mpox outbreak, infection from monkeypox virus was believed to offer long-term immunity. However, the first mpox reinfection in California was reported to the California Department Public of Health in April 2023. We sought to identify the frequency of mpox reinfections and associated characteristics to develop clinical and…

1158 – Distribution of HIV-1 Variants in Population-Based National Surveys in Sub-Saharan Africa, 2015-2022

Background The distribution of HIV-1 genetic variants among people living with HIV (PLHIV) is important for the design of vaccines and broadly neutralising antibodies (bNAbs) as well as for the accuracy of tests for diagnosis and viral load. This study aimed to compare the distribution of HIV-1 variants from population-based national surveys in sub-Saharan countries.…

1186 – Transfusion Risk of HIV, HBV, and HCV in Low- and Middle-Income Countries Without Nucleic Acid Testing

Background Nucleic acid testing (NAT) is a highly sensitive detection method routinely used to screen donated blood for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) in high-income countries. Despite this technology being available for decades, few low- and middle-income countries (LMIC) in sub-Saharan Africa (SSA) have implemented NAT. We…

1354 – Expanding the PrEP Market: Early Insights Offering Oral, Ring, and CAB PrEP in Sub-Saharan Africa

Background Adapting PrEP service delivery to a multi-method market requires real world data on uptake and use patterns. We evaluated method uptake and associated factors, switching and continuation among women offered oral PrEP, the dapivirine ring (PrEP ring), or injectable cabotegravir (CAB PrEP) in the CATALYST study.  Methods The CATALYST implementation study offered women a…

1234 – Qualitative Assessment of Acceptability and Preferences for Injectable and Oral PrEP in PURPOSE 1

Background PURPOSE 1 demonstrated 100% efficacy of twice-yearly injectable lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP) in cisgender adolescent girls and young women. We conducted a nested qualitative sub-study exploring acceptability, preferences, and experiences with LEN and daily oral emtricitabine plus tenofovir alafenamide (F/TAF) or tenofovir disoproxil fumarate (F/TDF) for PrEP during the randomized blinded…

1207 – Spillover Infections Drive Transmission in HIV Prevention Trials: BCPP/Ya Tsie Study

Background A longstanding puzzle in efforts to control the spread of HIV, is why HIV treatment-as-prevention efforts in sub-Saharan Africa showed modest reductions in the occurrence of new infections despite achieving substantial gains in viral suppression. Methods Using data from a community-randomized trial of HIV prevention in sub-Saharan Africa we offer for the first time an…

1313 – Enhanced Language Models for Predicting and Understanding HIV Care Disengagement

Background Despite significant progress in HIV treatment, maintaining patient engagement in care remains a critical challenge. While UNAIDS aims to achieve the “95-95-95” targets by 2030, many people living with HIV (PLHIV), particularly in sub-Saharan Africa, tend to discontinue care within two years. Current one-size-fits-all interventions often lack efficient targeting, and resources could be better…